

Fraud Committed by Pfizer and the FDA in the Continued Distribution of COVID-19 Vaccine. Letter Putting Colleges and Universities on Notice

Presidents, senior leadership and trustees can't say they didn't know.

By [No College Mandates](#)

Global Research, June 16, 2022

[No College Mandates Substack](#) 13 June 2022

Region: [USA](#)

Theme: [Law and Justice](#), [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Visit and follow us on [Instagram](#), [Twitter](#) and [Facebook](#). Feel free to repost and share widely Global Research articles.

No College Mandates has launched a major letter campaign to put colleges on notice that continued Covid-19 vaccination mandates put their students, their reputations, and potentially their endowments at risk. The purpose of the letter is to make these policy makers aware of new information they likely did not know existed and to prompt them to further investigate.

To date, more than 60 college presidents have received this letter via certified mail. Across those 60 colleges, approximately 1400 individuals were copied. Many more college letters are in process. By the time we are finished, thousands of college administrators and trustees will be notified.

No College Mandates is so proud to have the following organizations as signatories on our letter: [Health Freedom Defense Fund](#), [The Mendenhall Law Group](#), [Health Freedom Counsel](#), and [The Unity Project](#).

The letter is below. If you are interested in working on this effort, email us at info@nocollegemandates.com. We'll set you up to fight this fight with us and make change.

To College and University Presidents, Senior Leadership and Trustees:

We are writing to notify you of recently available information prompting concern that fraud has been committed by Pfizer and by the FDA in the development and continued distribution of Pfizer's Covid-19 vaccine. Given that your institution mandates Covid-19 vaccination for

students as a condition of enrollment, it is incumbent upon you to be fully informed about the safety and efficacy of these vaccines and the claims of fraud that call both into question.

If fraud or willful misconduct is proven, the manufacturers and those involved in the distribution or mandating of the vaccines will lose immunity from liability granted to them under the existing EUA and the PREP act.

We urge you to further investigate. We believe that once you do, you will see how continued Covid-19 vaccine mandates jeopardize the safety of your students and the reputation of your institution.

The new information consists of Pfizer's biological product file used to obtain FDA approval of Comirnaty and data from the insurance industry showing a huge rise in excess deaths in Millennial and Gen X populations concurrent with the implementation of vaccine approvals and mandates. The excess death data is raising concerns in the insurance industry and on Wall Street. We are also including timely news about product safety, given the FDA's recent restriction of the Johnson & Johnson vaccine due to blood clotting concerns.

Following is a brief overview of each category and starting points for further inquiry. We are standing by to provide you with additional information or to connect you to scientists, lawyers and investors who are reviewing the current and evolving data.

Pfizer Biological Product File – background and highlights:

The [Public Health and Medical Professionals for Transparency](#) (PHMPT) is a nonprofit group made up of public health professionals, medical professionals, scientists, and journalists. The group exists solely to obtain and disseminate the data relied upon by the FDA to license Covid-19 vaccines. Four days after the Pfizer Covid-19 vaccine was approved for children over 16, this group [submitted](#) a Freedom of Information Act for all data within Pfizer's Covid-19 vaccine biological product file. When the FDA asked for 75 years to release that data, PHMPT [sued](#) to obtain it and won. Beginning in March 2022, the public has access to Pfizer's clinical trial data, which is being downloaded in batches monthly. You can find the document releases to-date [here](#).

Thousands of volunteers including scientists, statisticians, doctors, and lawyers continue to examine these downloads and publish their findings. For ready reference, below are *just a few* of the findings of greatest concern that call into question the safety and efficacy of the Pfizer product and support a thesis of fraud:

- Pfizer failed the all-cause mortality endpoint in their unprecedentedly short 28-day clinical trial. In brief, *more people died in the vaccinated group* than in the placebo group. This was known yet has still not been widely disclosed to the public.
- The CDC talking point that vaccines stopped transmission was based on no data, as this metric was *notevaluated* during Pfizer's clinical trials. Pfizer and the FDA knew this yet did not disclose it to the public.
- Pfizer and the FDA *knew* as early as November 2020 that Pfizer's clinical trials showed:
 - Vaccine failure
 - Waning vaccine efficacy

A baseline condition for granting a product Emergency Use Authorization is that it must be

safe and *effective*. The data showed that the products are not effective. Yet, based on FDA approval, the CDC promoted them as such. From the initial roll-out in December 2020 through April 1, 2021, the public health messaging was that if you received the shot, you could not get infected and could not transmit the virus. The Pfizer documents are proof that they and the FDA colluded to lie *to the American people and the CDC created false public health narratives based on these lies*.

- Pfizer and the FDA most likely *knew* in May 2021 that the vaccines caused heart damage in teenagers based on a [paper](#) that was already in peer review at that time. The FDA approved the product for teenagers in June 2021 yet did not disclose this risk factor to consumers until August. During that time, all those who received this product did not have informed consent. Parents were not made aware of this known potential risk to their children.
- Brook Jackson, a regional director employed by Pfizer sub-contractor Ventavia Research Group, came forward in September 2020 with documented evidence that the company falsified data, unblinded patients and was slow to follow up on adverse events reported in Pfizer's pivotal phase III trial conducted by Ventavia. Her findings call into question the integrity of not only Ventavia's results but of all of the results from Pfizer's other trial sites and the entire clinical trial. Further information is available in [The British Medical Journal](#).

Excess death data and the insurance industry:

In December 2021, Midwest insurer One America CEO Scott Davidson [disclosed](#) a 40% increase in excess deaths over pre-pandemic levels in the working-age (18-64) population in the third quarter. Putting the number into context Davidson said, *"The data is consistent across every player in this business . . . Just to give you an idea of how bad that is, a three-sigma or a one-in-200-year catastrophe would be a 10 percent increase over pre-pandemic. So 40 percent is just unheard of"*. Other major insurers have subsequently reported increases in death claims ranging from 21-57 % over expected levels. Most of these deaths are not Covid-19 deaths. Long-term disability claims are also seeing an uptick.

These reports prompted a former institutional investor who was a #1 ranked Wall Street sell-side insurance analyst to confirm the numbers using CDC reported data. His findings, [independently confirmed](#) by others, show the spikes in excess deaths are related to the timing of vaccine approvals and mandates. This data is prompting concern at insurance and reinsurance companies, who will bear the financial brunt of this unexpected and unprecedented rise in mortality. It is raising questions about the safety of the Covid-19 vaccines in the investment community and beyond.

Of related interest is Pfizer's amendment in February of its business risk disclosures in its [Q4 2021 earnings report](#). The changes from the [Q3 2021 report language](#) center around disclosures of unfavorable safety data and "further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection".

It is likely that neither Pfizer nor the FDA anticipated the court-compelled release of their clinical trial and post-marketing surveillance data and the subsequent public scrutiny of it.

Additional product safety concerns:

The FDA [announced](#) on May 5 that they were restricting use of the Johnson & Johnson

Covid-19 vaccine due to the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets. The decision to restrict was based on 60 reported cases and 9 fatalities. The Pfizer and Moderna vaccines also have serious risks and fatalities associated with them including but not limited to blood clots and myocarditis in college-aged populations. These are shown in Pfizer's post-marketing surveillance [data](#) and in the CDC's Vaccine Adverse Event Recording System (VAERS). As of April 29, 2022, there were approximately 1.2 million reports of adverse events following Covid-19 vaccination including more than 18,056 reports of deaths following the Pfizer vaccine, and 7,223 following the Moderna vaccine. Logic demands that Pfizer and Moderna products be restricted immediately as well. Why have they not been? Further, a recent [Danish review](#) of all three products in preprint in *The Lancet* showed that the J&J reduced all-cause mortality but that Pfizer and Moderna did not and may have increased it. Given all this, it is reasonable to think that Pfizer and Moderna products could be restricted or discontinued very soon due to safety concerns. This might well trigger a much higher level of scrutiny of the now-publicly available Pfizer data and the actions of our public health institutions. *How would such a situation impact institutions such as yours that continue to mandate the products while knowing such risks exist?*

One last thing to consider is the nature and associated secrecy of the contracts that Pfizer forced upon governments as conditions of sale and distribution of their Covid-19 vaccines in their respective countries. A review of some of these contracts can be found [here](#). Terms included such things as the waiving of sovereign immunity, countries assuming full liability in the event that Pfizer was shown to have used another entity's intellectual property, and that Pfizer be held harmless in the event of injury or death from the products. Why would a company require such terms if it knew its conduct and its products were sound?

We sincerely hope this information has been useful and that you will investigate this matter fully. We urge you to end your vaccine mandates to protect your institution's students, reputation, and, in the event that fraud is proven, potentially your endowment.

Yours truly,

[No College Mandates](#)

[Health Freedom Defense Fund](#)

[The Mendenhall Law Group](#)

[Health Freedom Counsel](#)

[The Unity Project](#)

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, Twitter and Facebook. Feel free to repost and share widely Global Research articles.

Featured image is from LifeSiteNews

The original source of this article is [No College Mandates Substack](#)
Copyright © [No College Mandates](#), [No College Mandates Substack](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [No College
Mandates](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca